Sequence by WeightWatchersvsPlushCare Weight Loss

Sequence is a telehealth platform, not a drug. You complete an online health-history questionnaire, then have a video visit with a board-certified clinician who decides whether a prescription weight-loss medication is safe and appropriate for you. The medications prescribed are mostly GLP-1 (and dual GLP-1/GIP) receptor agonists such as semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda); non-GLP-1 options like metformin or naltrexone/bupropion may also be used when appropriate. These drugs mimic gut hormones that slow stomach emptying, blunt appetite, and increase fullness, so many people eat less without constant hunger. Layered on top is WeightWatchers' behavioral program: the Points food system, dietitian access, fitness guidance, and a GLP-1 Success Program focused on protein intake and muscle preservation during weight loss.

PlushCare itself is a telehealth platform, not a drug. You book a video visit with a board-certified physician who reviews your history, orders an obesity lab panel (typically CBC, a metabolic panel, lipids, A1C, TSH, and insulin, drawn through a lab such as Quest), and, if appropriate, prescribes a GLP-1 medication sent to your pharmacy. The medications work by mimicking gut hormones: semaglutide (Wegovy/Ozempic) activates GLP-1 receptors, while tirzepatide (Zepbound/Mounjaro) activates both GLP-1 and GIP receptors. They slow stomach emptying, reduce appetite, and increase fullness, so you tend to eat less and lose weight.

Real-world and trial evidence for these medications is genuinely strong, though the platform-specific figures should be read with caution. A 2024 retrospective analysis in the journal Obesity (Ard et al.) of the WeightWatchers/Sequence telehealth program reported that, among patients with complete data at 12 months, average weight loss was about 19.4% of initial body weight, with roughly 21.2% on tirzepatide and the semaglutide formulations (Wegovy and Ozempic) in the mid-teens, broadly 13 to 15 percent. A key caveat: of the 53,590 patients who started treatment, only about 6,089 had complete 12-month data, so these completer averages likely overstate typical results because people who stopped early or regained are underrepresented. These outcomes are broadly in line with the pivotal drug trials: semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks in STEP 1 (NEJM 2021); tirzepatide produced roughly 20.9% (15 mg, treatment-regimen estimand) and up to about 22.5% over 72 weeks in SURMOUNT-1 (NEJM 2022); and in the head-to-head SURMOUNT-5 trial (NEJM 2025) tirzepatide outperformed semaglutide, about 20.2% versus 13.7% at 72 weeks. Individual results vary widely and depend heavily on staying on the medication and engaging with the program.

PlushCare does not run its own trials; efficacy comes from the medications it prescribes. In the STEP 1 trial (NEJM 2021, 1,961 adults without diabetes), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% for placebo, with about 50.5% of users losing at least 15% of their body weight. In the SURMOUNT-1 trial (NEJM 2022, 2,539 adults), tirzepatide (Zepbound) produced mean reductions of about 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg doses over 72 weeks, versus roughly 2.4% for placebo. Results depend on reaching and staying on an effective dose, and weight tends to return if the medication is stopped. Compounded versions are not FDA-approved and have not been tested for the same bioequivalence, so results with them may differ.

The most common side effects come from the medications, not the platform, and are mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually worst when starting or increasing the dose and often easing over time. Slow dose titration and dietary adjustments can help. Less common but serious risks include an FDA boxed warning for thyroid C-cell tumors (based on rodent studies; human risk is not established), along with reported cases of pancreatitis, gallbladder disease and gallstones, kidney injury from dehydration, and, with tirzepatide, possible reduced absorption of oral contraceptives. Rapid weight loss can also cause loss of muscle mass, which the WW GLP-1 Success Program tries to counter with high-protein and strength guidance. Seek prompt medical attention for severe or persistent abdominal pain, persistent vomiting, or signs of an allergic reaction, and report concerning symptoms to your care team. This is not a complete list of side effects.

The side effects are those of the GLP-1 drugs themselves, not the platform. The most common are gastrointestinal: nausea, vomiting, diarrhea, constipation, and bloating, usually worst when starting or increasing the dose and often easing over time. Less common but serious risks include pancreatitis, gallbladder problems (including gallstones), and dehydration-related kidney injury from severe vomiting. These drugs carry an FDA boxed warning about thyroid C-cell tumors seen in rodents (the relevance to humans is unconfirmed, but they are contraindicated with a history of MTC or MEN 2). Tell your PlushCare doctor about severe or persistent abdominal pain, which can signal pancreatitis, and seek urgent care if it is intense.

As of 2026, WW Clinic / Med+ membership is commonly advertised at about $25/month for the first two to three months, then roughly $74/month for the remainder of a 12-month plan, with month-to-month options reported around $149/month. Membership covers clinician visits, insurance coordination, labs, coaching, and the WW app, but the medication is billed separately. List prices for brand-name GLP-1s can run roughly $1,000 to $1,350 per month, but few people pay that: WeightWatchers and the manufacturers offer cash-pay programs that are far lower (for example, Novo Nordisk's self-pay Wegovy oral tablet has been offered near $149/month and WW has advertised cash-pay injectable starter pricing well under list), and commercial insurance, where it covers weight-loss GLP-1s, can drop out-of-pocket costs to roughly $25 to $150/month. Coverage and savings eligibility vary widely, so verify your specific plan and compare WW's drug pricing against pharmacy and manufacturer options before committing.

As of 2026, PlushCare charges a membership of about $19.99/month (often with a free first month) or roughly $99/year, plus consultation fees: about $129 per visit without insurance, or a copay (often $30 or less) with in-network insurance. These fees cover only the platform and doctor; the medication is billed separately. Brand-name GLP-1s can reach roughly $1,000+ per month at full retail if insurance denies coverage, but PlushCare also advertises promotional cash-pay brand pricing at times (for example, Ozempic and Wegovy near $199/month for the first two months, then higher) and offers compounded semaglutide in eligible states at around $149/month for the lowest dose and about $299/month for higher doses, which is paid out of pocket and does not run through insurance. PlushCare can attempt prior authorization for brand drugs, but GLP-1 coverage is never guaranteed and the process can take up to about two weeks. Confirm current pricing at signup, since promotional rates change.

The program is designed for US adults who meet clinical criteria for anti-obesity medication, typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. The clinician makes the final call after reviewing your history and, in many cases, lab work. GLP-1 medications are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), and they should not be used in pregnancy or by people with a prior serious hypersensitivity reaction to the drug. People with a history of pancreatitis, gallbladder disease, gastroparesis, kidney problems, or diabetic retinopathy need careful evaluation. The program is not a substitute for in-person care and is not appropriate for those seeking medication without medical oversight.

PlushCare's program is for US adults who medically qualify for a GLP-1: generally a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. These drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and should not be used by people with a prior serious reaction to them. They are not recommended in pregnancy or breastfeeding, and people with a history of pancreatitis, gallbladder disease, gastroparesis or other severe GI disorders, diabetic retinopathy, or significant kidney impairment need careful physician evaluation. Final eligibility is decided by the prescribing doctor, not automatically.